Aastrom stem cell therapy has high success rate

Mon, 22 Oct 2007 06:59:55 -0400

In a small stem cell study involving 33 patients, researchers for Aastrom Biosciences are reporting a 91 percent success rate in repairing hard-to-heal fractures. All of the patients in the study had experienced breaks that did not heal despite the use of standard therapies. And the majority of them had healed a year after the stem cell therapy was injected at the break point.

"The positive results from this study, along with early clinical data reported from osteonecrosis patients two weeks ago, further supports the broad application of our proprietary TRC Technology in the field of orthopedics," said George Dunbar, president and CEO of Aastrom. "We believe these early successes with our technology are important for attracting an experienced orthopedics partner to commercialize our BRC product for bone regeneration."

- here's the release for more info

Related Article:
MIT study offers advance in stem cell therapy. Report

ALSO NOTED: Galapagos gains development grants;Aastrom to sell stock; and much more...

Tue, 16 Oct 2007 06:59:50 -0400

> Galapagos has garnered €5.2 million in grant money to continue its drug development work. Release

> Aastrom Biosciences is raises $13.5 million in a stock offering. Release

> Chutes & Ladders: Fresh from raising $35 million from a Series B of venture capital, Metastatix has named Carol Gallagher as its new president and CEO. Release (.pdf)

> BioSynthema has inked a deal to use Covidien technology to develop a new, targeted radionuclide therapy product. Release

> Boston Scientific is poised to join its healthcare colleagues in laying off thousands of workers. Report

> Last week, the buzz about GlaxoSmithKline's CEO-presumptive Andrew Witty included worries that his internal competitors for the top slot would jump ship. Now Glaxo may sweeten the pot for those also-rans--by putting them on the board of directors. Report

> Here's Exhibit Z in the long list of reasons why Big Pharma wants to make deals with biotech--and why speculation about Biogen and Genzyme is running so high. Roche and Genentech are both reaping a big harvest from their joint cancer drugs this quarter. Report

> Low doses of a human antibody in mice were effective in repairing damaged myelin, a protective shield for nerves that is destroyed by multiple sclerosis. Report

And Finally... Who is most likely to buy Biogen Idec? Poll